Drugs / trabodenoson
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01123772 | May 2010 → Feb 2011 | — | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01123785 | May 2010 → Dec 2011 | glaucoma, ocular hypertension | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02829996 | Aug 2016 → May 2017 | ocular hypertension, open-angle glaucoma | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01917383 | Aug 2013 → Aug 2014 | ocular hypertension, open-angle glaucoma | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02565173 | Sep 2015 → Nov 2016 | ocular hypertension, open-angle glaucoma | Inotek Pharmaceuticals Corporation | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trabodenoson | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02565173 ↗ |
| Known as | INNO-8875 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545407 ↗ |
| Known as | INO-8875 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01123772 ↗ |
| Known as | PJ-875 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545407 ↗ |
| Action | Activate | “Adenosine A1 receptor agonist” CHEMBL3545407 ↗1“Adenosine agonist eye drop” NCT01123785 ↗ |
| Modality | Small molecule | — CHEMBL3545407 ↗ |
| Route | Topical | “Topical Ocular Application of INO-8875” NCT01123772 ↗ |
| Target | ADORA1 | “Adenosine A1 receptor agonist” CHEMBL3545407 ↗ |